Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pall Opens New Life Sciences CoE in Shanghai

Published: Thursday, October 17, 2013
Last Updated: Thursday, October 17, 2013
Bookmark and Share
New Centre of Excellence extends Pall’s local capabilities in the region.

Pall Corporation has inaugurated the Pall Life Sciences Centre of Excellence (CoE) at its new Zhangjiang site in Shanghai in the People’s Republic of China.

The new Centre of Excellence, which offers biopharmaceutical process solutions, technical and validation support as well as training, extends Pall’s local capabilities for its growing base of life sciences customers in the region.

“This year marks the 20th anniversary of Pall’s expansion into China. The opening of the Shanghai Life Sciences Centre of Excellence is another milestone in Pall’s development in China,” said Larry Kingsley, Chairman and CEO of Pall Corporation.

Kingsley continued, “The new Centre of Excellence not only reinforces our commitment to investing in the region, but also makes it easier for customers in the area to do business with us.”

The new CoE is fully equipped with the most advanced capabilities for process demonstration, testing and validation. Customers also can consult with Pall experts about equipment selection, installation and adjustment.

Integrated with the CoE at the Shanghai facility is a branch office that serves both the company’s Life Sciences and Industrial customers.

More than 200 employees work at the 8,600 m2 Shanghai facility, which provides filtration, separation and purification solutions for a range of industries. These include biopharmaceuticals, medical, food & beverage, process technologies, aerospace and microelectronics.

“China is an important market for Pall and long-term, favorable economic trends give us the confidence to continue development in the potentially high-growth region,” said Hang Gek Low, Vice President of Pall China.

Low continued, “The establishment of the Shanghai CoE enhances our ability to service customers in the area while enabling us to provide dedicated support for Chinese enterprises exploring overseas markets.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pall Corp. Signs Agreement with ATMI
Agreement to acquire ATMI’s LifeSciences business for $185 million.
Friday, December 27, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos